GREAT POINT PARTNERS LLC — 13F Holdings & Portfolio
CIK 1281446 · latest 13F-HR filed 2026-08-14
GREAT POINT PARTNERS LLC manages $529.1M in 13F-reported U.S. long-equity assets across 42 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ABVX (10.07%), VOR (5.91%), ABVX (5.15%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions, exited 13, added to 14, and trimmed 9.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
GREENWICH, CT 06830
$529.1M
Long-equity book
42
Distinct positions
2026-06-30
Filed 2026-08-14
+11 / −13 / ↑14 / ↓9
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- VERA THERAPEUTICS INC$17.8M +221.5%
- IMMIX BIOPHARMA INC$10.0M +313.1%
- ORUKA THERAPEUTICS INC$8.5M +94.0%
- MOONLAKE IMMUNOTHERAPEUTICS$7.3M +78.8%
- OPUS GENETICS INC$6.6M +448.7%
Top Trims
- AMYLYX PHARMACEUTICALS INC-$11.8M -48.3%
- NEKTAR THERAPEUTICS-$10.6M -46.3%
- BRIGHT MINDS BIOSCIENCES INC-$8.4M -52.1%
- PROMIS NEUROSCIENCES INC-$3.6M -76.0%
- EVOMMUNE INC-$3.2M -42.2%
New Positions
- ABIVAX SA$27.2M
- DEFINIUM THERAPEUTICS INC$20.0M
- SAGIMET BIOSCIENCES INC$15.7M
- INFLARX NV$6.8M
- JATT II ACQUISITION CORP$5.7M
Exited Positions
- APOGEE THERAPEUTICS INC$31.5M
- KALVISTA PHARMACEUTICALS INC$13.6M
- IMMUNOVANT INC$13.6M
- JADE BIOSCIENCES INC$13.6M
- ZENAS BIOPHARMA INC$10.2M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ABIVAX SA Call | ABVX | 00370M103 | $53.3M | 10.07% | 400,000 | SH |
| 2 | VOR BIOPHARMA INC | VOR | 929033207 | $31.3M | 5.91% | 1,700,000 | SH |
| 3 | ABIVAX SA | ABVX | 00370M103 | $27.2M | 5.15% | 204,314 | SH |
| 4 | IMMUNITYBIO INC Put | IBRX | 45256X103 | $26.3M | 4.97% | 3,000,800 | SH |
| 5 | VERA THERAPEUTICS INC | VERA | 92337R101 | $25.8M | 4.87% | 600,836 | SH |
| 6 | ZURA BIO LTD | ZURA | G9TY5A101 | $24.9M | 4.70% | 4,215,930 | SH |
| 7 | ALUMIS INC | ALMS | 022307102 | $24.1M | 4.55% | 856,061 | SH |
| 8 | SOL-GEL TECHNOLOGIES LTD | SLGL | M8694L137 | $20.3M | 3.84% | 274,363 | SH |
| 9 | ULTRAGENYX PHARMACEUTICAL IN Put | RARE | 90400D108 | $20.0M | 3.79% | 600,000 | SH |
| 10 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $20.0M | 3.78% | 425,000 | SH |
| 11 | ANNEXON INC | ANNX | 03589W102 | $20.0M | 3.78% | 3,500,000 | SH |
| 12 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $17.4M | 3.30% | 183,330 | SH |
| 13 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $16.7M | 3.15% | 855,813 | SH |
| 14 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $15.7M | 2.97% | 2,029,933 | SH |
| 15 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $15.1M | 2.85% | 921,481 | SH |
| 16 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $13.2M | 2.49% | 1,277,642 | SH |
| 17 | CLIMB BIO INC | CLYM | 28658R106 | $13.0M | 2.46% | 1,000,000 | SH |
| 18 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $12.6M | 2.38% | 700,000 | SH |
| 19 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $12.2M | 2.31% | 175,000 | SH |
| 20 | NEUROGENE INC | NGNE | 64135M105 | $11.1M | 2.09% | 352,180 | SH |
| 21 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $10.3M | 1.95% | 317,221 | SH |
| 22 | OPUS GENETICS INC | IRD | 67577R102 | $8.1M | 1.53% | 1,970,187 | SH |
| 23 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $7.9M | 1.50% | 1,200,000 | SH |
| 24 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $7.7M | 1.45% | 109,603 | SH |
| 25 | INFLARX NV | IFRX | N44821101 | $6.8M | 1.29% | 3,046,557 | SH |
| 26 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $5.8M | 1.10% | 842,106 | SH |
| 27 | JATT II ACQUISITION CORP | JATT | G50765109 | $5.7M | 1.07% | 500,000 | SH |
| 28 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $5.5M | 1.03% | 300,000 | SH |
| 29 | ALTIMMUNE INC | ALT | 02155H200 | $5.3M | 1.00% | 1,741,232 | SH |
| 30 | AMANAT ACQUISITION CORP | AMAN | G0375M101 | $5.1M | 0.96% | 500,000 | SH |
| 31 | REZOLUTE INC | RZLT | 76200L309 | $4.9M | 0.94% | 951,809 | SH |
| 32 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $4.9M | 0.93% | 450,000 | SH |
| 33 | PALISADE BIO INC | PALI | 696389402 | $4.8M | 0.90% | 2,284,819 | SH |
| 34 | EVOMMUNE INC | EVMN | 30054Y107 | $4.3M | 0.82% | 325,000 | SH |
| 35 | SCYNEXIS INC | SCYX | 811292309 | $3.8M | 0.73% | 944,292 | SH |
| 36 | GALECTIN THERAPEUTICS INC Call | GALT | 363225202 | $3.7M | 0.70% | 800,000 | SH |
| 37 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $3.6M | 0.67% | 70,000 | SH |
| 38 | HUMACYTE INC | HUMA | 44486Q103 | $2.9M | 0.55% | 3,750,000 | SH |
| 39 | REIN THERAPEUTICS INC | RNTX | 00887A204 | $2.7M | 0.51% | 2,575,000 | SH |
| 40 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $2.6M | 0.49% | 156,906 | SH |
| 41 | ANAVEX LIFE SCIENCES CORP Call | AVXL | 032797300 | $1.4M | 0.26% | 521,300 | SH |
| 42 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $1.1M | 0.21% | 86,150 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $529.1M | 42 | 0001172661-26-003750 |
| 2026-03-31 | 2026-05-15 | $435.1M | 42 | 0001172661-26-002272 |
| 2025-12-31 | 2026-02-17 | $308.4M | 29 | 0001172661-26-001093 |
| 2025-09-30 | 2025-11-14 | $242.5M | 30 | 0001814554-25-000164 |